Download PDF
Horm Metab Res 2017; 49(07): 507-509
DOI: 10.1055/s-0043-109866
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Metabolic Syndrome and Aggressive Prostate Cancer at Initial Diagnosis

Simona Di Francesco
1   Department of Medical and Oral Sciences and Biotechnologies, G. D’Annunzio University of Chieti-Pescara, Chieti, Italy
,
Raffaele L. Tenaglia
1   Department of Medical and Oral Sciences and Biotechnologies, G. D’Annunzio University of Chieti-Pescara, Chieti, Italy
› Author Affiliations
Further Information

Publication History

received 30 March 2017

accepted 24 April 2017

Publication Date:
11 May 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Links between metabolic syndrome and prostate cancer after androgen deprivation therapy are emerging. The aim of the research was to investigate the association of metabolic syndrome and aggressive prostate malignancy, at initial diagnosis, without the influence of hormonal treatment. Retrospective analysis of 133 patients with prostate tumor diagnosis between 2007 and 2009 was conducted. Patients with prostate cancer were subdivided in 2 groups according to Gleason score: Gleason score≥7 as high-grade prostate tumor (Group 1) and <7 (Group 2) as low-grade prostate tumor. Metabolic syndrome was defined according to International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute definition. Metabolic syndrome was significantly associated with aggressive prostate cancer (OR 1.87, p<0.05) and a reduced risk of low-grade prostate cancer (OR 0.53, p<0.05) at initial diagnosis, without the influence of endocrine therapy. In our study, patients with metabolic syndrome were more likely to present with more aggressive prostate carcinoma vs. patients without metabolic syndrome. Further research should elucidate these relations in larger samples to confirm these associations and to stabilize future prevention and therapeutic strategies.

Key words

metabolic syndrome - prostate carcinoma - hormonal therapy
 

  • References

  • 1 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. International diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; international association for the study of obesity. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009; 120: 1640-1645
    PubMedGoogle Scholar
  • 2 Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, Lenzi A, Giugliano D. Effect of metabolic syndrome and its components on prostate cancer risk: meta analysis. J Endocrinol Invest 2013; 36: 132-139
    CrossrefPubMedGoogle Scholar
  • 3 Di Francesco S, Tenaglia RL. Metabolic alterations, vascular disease and advanced prostate cancer. New Players For Metastatic Advanced Prostate Cancer?. J Anal Oncol 2014; 3: 33-35
    PubMedGoogle Scholar
  • 4 Di Francesco S, Tenaglia RL. Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis. Cent Eur J Urol 2013; 66: 423-427
    PubMedGoogle Scholar
  • 5 Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102
    CrossrefPubMedGoogle Scholar
  • 6 Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, Tubaro A, Morgia G, Serni S. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis 2017; DOI: 10.1038/pcan.2017.1. [Epub ahead of print]
    PubMedGoogle Scholar
  • 7 Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol 2015; 67: 64-70
    CrossrefPubMedGoogle Scholar
  • 8 Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res 2013; 32: 9
    CrossrefPubMedGoogle Scholar
  • 9 Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411
    CrossrefPubMedGoogle Scholar
  • 10 Häggström C, Stocks T, Ulmert D, Bjørge T, Ulmer H, Hallmans G, Manjer J, Engeland A, Nagel G, Almqvist M, Selmer R, Concin H, Tretli S, Jonsson H, Stattin P. Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012; 118: 6199-6206
    CrossrefPubMedGoogle Scholar
  • 11 Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol. 2011; 21: 835-841
    CrossrefPubMedGoogle Scholar
  • 12 Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol 2012; 53: 593-597
    CrossrefPubMedGoogle Scholar
  • 13 Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2013; 111: 1031-1036
    CrossrefPubMedGoogle Scholar
  • 14 De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, Tubaro A. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 1492-1498
    CrossrefPubMedGoogle Scholar
  • 15 Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, Sharma P, Menon M, Agarwal PK. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol 2013; 31: 1054-1059
    CrossrefPubMedGoogle Scholar
  • 16 Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774
    CrossrefPubMedGoogle Scholar
  • 17 Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650
    PubMedGoogle Scholar
  • 18 Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881
    CrossrefPubMedGoogle Scholar
  • 19 Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185-190
    CrossrefPubMedGoogle Scholar
  • 20 Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102
    CrossrefPubMedGoogle Scholar
  • 21 Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181-1192
    CrossrefPubMedGoogle Scholar
  • 22 Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011; 22: 801-807
    CrossrefPubMedGoogle Scholar
  • 23 Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. Adv Urol 2012; 248607
    PubMedGoogle Scholar
  • 24 Akinloye O, Blessing Popoola B, Bolanle Ajadi M, Gregory Uchechukwu J, Pius Oparinde D. Hypogonadism and metabolic syndrome in nigerian male patients with both type 2 diabetes and hypertension. Int J Endocrinol Metab 2014; 12: e10749
    PubMedGoogle Scholar
  • 25 Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol 2013; 9: 479-493
    CrossrefPubMedGoogle Scholar
  • 26 Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5: 673-681
    CrossrefPubMedGoogle Scholar
  • 27 Guay AT. The emerging link between hypogonadism and metabolic syndrome. J Androl 2009; 30: 370-376
    CrossrefPubMedGoogle Scholar
  • 28 Di Francesco S, Castellan P, Manco R, Tenaglia RL. Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review. Cent Eur J Urol 2011; 64: 201-204
    PubMedGoogle Scholar
  • 29 Di Francesco S, Tenaglia RL. Bone metabolism, renal function and immune structure in prostate cancer. Our experience. Rec Prog Med 2013; 104: 28-32
    PubMedGoogle Scholar
  • 30 Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 2004; 44: 248-252
    CrossrefPubMedGoogle Scholar
  • 31 Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?. Urol Res 2012; 40: 95-112
    CrossrefPubMedGoogle Scholar
  • 32 Virdis A, Neves MF, Duranti E, Bernini G, Taddei S. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des 2013; 19: 2382-2389
    CrossrefPubMedGoogle Scholar